TScan Therapeutics (TCRX)
TScan Therapeutics on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq.
2.3M
Short interest
settlement 2026-10-15
3.4
Days to cover
+0.1 days vs prior
66.2%
Short share of volume
2026-11-02
35,120
Fails to deliver
settlement 2026-10-14
Wed 11 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in TCRX is 2,277,116 shares, down 3,047 shares over the last month. Over the last 48 readings it ranged from 708,200 shares (30 June 2026) to 2,566,263 shares (30 January 2026). At the reported average volume of 669K shares a day that is 3.4 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/tcrx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 2,277,116 | -8.4% | 669,359 | 3.40 |
| 2026-09-30 | 2,486,277 | +9.0% | 764,430 | 3.25 |
| 2026-09-15 | 2,280,163 | +30.3% | 1,966,155 | 1.16 |
| 2026-08-31 | 1,749,828 | +9.3% | 250,997 | 6.97 |
| 2026-08-14 | 1,601,066 | +2.7% | 377,894 | 4.24 |
| 2026-07-31 | 1,558,905 | +12.6% | 560,685 | 2.78 |
| 2026-07-15 | 1,384,530 | +95.5% | 1,160,818 | 1.19 |
| 2026-06-30 | 708,200 | -7.1% | 782,925 | 1.00 |
| 2026-06-15 | 762,526 | -18.4% | 392,390 | 1.94 |
| 2026-05-29 | 934,310 | +6.6% | 457,592 | 2.04 |
| 2026-05-15 | 876,559 | +0.7% | 840,606 | 1.04 |
| 2026-04-30 | 870,161 | -7.7% | 1,098,631 | 1.00 |
| 2026-04-15 | 942,877 | -50.0% | 1,566,620 | 1.00 |
| 2026-03-31 | 1,885,270 | -0.4% | 500,400 | 3.77 |
| 2026-03-13 | 1,892,903 | -1.9% | 702,720 | 2.69 |
| 2026-02-27 | 1,930,510 | -3.7% | 428,150 | 4.51 |
| 2026-02-13 | 2,003,903 | -21.9% | 460,887 | 4.35 |
| 2026-01-30 | 2,566,263 | +8.7% | 485,094 | 5.29 |
| 2026-01-15 | 2,360,339 | +13.6% | 555,924 | 4.25 |
| 2025-12-31 | 2,077,294 | -18.2% | 625,472 | 3.32 |
| 2025-12-15 | 2,539,912 | +8.7% | 775,729 | 3.27 |
| 2025-11-28 | 2,335,680 | +19.8% | 850,678 | 2.75 |
| 2025-11-14 | 1,949,768 | +11.9% | 1,348,069 | 1.45 |
| 2025-10-31 | 1,742,176 | +4.0% | 569,461 | 3.06 |
| 2025-10-15 | 1,675,616 | +6.9% | 959,807 | 1.75 |
| 2025-09-30 | 1,567,792 | -9.0% | 277,361 | 5.65 |
| 2025-09-15 | 1,722,543 | +0.7% | 238,606 | 7.22 |
| 2025-08-29 | 1,711,155 | -7.7% | 201,892 | 8.48 |
| 2025-08-15 | 1,853,155 | +7.9% | 229,311 | 8.08 |
| 2025-07-31 | 1,717,845 | -6.3% | 303,486 | 5.66 |
| 2025-07-15 | 1,833,410 | -7.3% | 327,431 | 5.60 |
| 2025-06-30 | 1,978,866 | -12.8% | 928,714 | 2.13 |
| 2025-06-13 | 2,268,054 | +12.6% | 401,977 | 5.64 |
| 2025-05-30 | 2,014,752 | -12.5% | 1,264,002 | 1.59 |
| 2025-05-15 | 2,303,027 | +28.4% | 258,986 | 8.89 |
| 2025-04-30 | 1,793,660 | -1.3% | 519,046 | 3.46 |
| 2025-04-15 | 1,816,555 | -10.3% | 472,348 | 3.85 |
| 2025-03-31 | 2,025,238 | +6.6% | 580,834 | 3.49 |
| 2025-03-14 | 1,900,134 | -14.6% | 321,717 | 5.91 |
| 2025-02-28 | 2,225,112 | +11.1% | 625,050 | 3.56 |
| 2025-02-14 | 2,002,749 | +10.1% | 252,583 | 7.93 |
| 2025-01-31 | 1,818,854 | -9.0% | 204,704 | 8.89 |
| 2025-01-15 | 1,998,350 | -20.7% | 389,298 | 5.13 |
| 2024-12-31 | 2,519,323 | +7.3% | 687,562 | 3.66 |
| 2024-12-13 | 2,346,815 | +1.3% | 665,922 | 3.52 |
| 2024-11-29 | 2,317,690 | +0.9% | 170,070 | 13.63 |
| 2024-11-15 | 2,295,860 | +6.1% | 339,886 | 6.75 |
| 2024-10-31 | 2,164,450 | -3.5% | 156,955 | 13.79 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of TCRX volume is 66.2%, up 25.0 points over the last five sessions. Over the last 30 readings it ranged from 17.6% (25 September 2026) to 75.6% (6 October 2026). The latest reading is 16.3 points above the 30-session average of 49.9%, on 294K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 194K | 294K | 66.2% | 3,693 |
| 2026-10-30 | 42K | 138K | 30.7% | 2 |
| 2026-10-29 | 23K | 37K | 62.8% | 2,800 |
| 2026-10-28 | 78K | 174K | 44.8% | 0 |
| 2026-10-27 | 87K | 222K | 39.0% | 22,000 |
| 2026-10-26 | 111K | 268K | 41.3% | 20,992 |
| 2026-10-23 | 66K | 130K | 50.7% | 0 |
| 2026-10-22 | 99K | 152K | 64.8% | 0 |
| 2026-10-21 | 301K | 443K | 67.8% | 0 |
| 2026-10-20 | 203K | 302K | 67.3% | 0 |
| 2026-10-19 | 149K | 249K | 59.9% | 0 |
| 2026-10-16 | 169K | 334K | 50.5% | 0 |
| 2026-10-15 | 236K | 559K | 42.3% | 0 |
| 2026-10-14 | 142K | 306K | 46.6% | 22,874 |
| 2026-10-13 | 130K | 255K | 50.9% | 2,729 |
| 2026-10-12 | 67K | 242K | 27.8% | 0 |
| 2026-10-09 | 257K | 515K | 50.0% | 25,733 |
| 2026-10-08 | 416K | 897K | 46.4% | 52,261 |
| 2026-10-07 | 116K | 369K | 31.6% | 33,514 |
| 2026-10-06 | 257K | 340K | 75.6% | 62,925 |
| 2026-10-05 | 332K | 463K | 71.7% | 29,259 |
| 2026-10-02 | 52K | 84K | 61.9% | 0 |
| 2026-10-01 | 198K | 464K | 42.7% | 500 |
| 2026-09-30 | 164K | 327K | 50.3% | 0 |
| 2026-09-29 | 144K | 371K | 38.8% | 0 |
| 2026-09-28 | 90K | 238K | 37.7% | 0 |
| 2026-09-25 | 43K | 246K | 17.6% | 0 |
| 2026-09-24 | 218K | 364K | 59.8% | 0 |
| 2026-09-23 | 227K | 674K | 33.7% | 0 |
| 2026-09-22 | 466K | 703K | 66.3% | 150 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in TCRX is 35,120 shares, down 3,366 shares over the last settlement date. Over the last 30 readings it ranged from 21 shares (9 October 2026) to 78,382 shares (4 May 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 35,120 | $0.22 | $8K |
| 2026-10-13 | 38,486 | $0.24 | $9K |
| 2026-10-09 | 21 | $0.23 | $5 |
| 2026-09-25 | 2,286 | $0.35 | $800 |
| 2026-09-18 | 9,387 | $0.33 | $3K |
| 2026-09-17 | 4,108 | $0.33 | $1K |
| 2026-09-16 | 7,015 | $0.32 | $2K |
| 2026-09-10 | 4,663 | $0.33 | $2K |
| 2026-09-08 | 10,536 | $0.39 | $4K |
| 2026-09-03 | 10,491 | $0.38 | $4K |
| 2026-08-31 | 14,974 | $0.75 | $11K |
| 2026-08-28 | 8,544 | $0.75 | $6K |
| 2026-08-27 | 4,177 | $0.78 | $3K |
| 2026-08-26 | 6,173 | $0.79 | $5K |
| 2026-08-07 | 9,241 | $0.76 | $7K |
| 2026-07-17 | 16,834 | $0.90 | $15K |
| 2026-07-16 | 20,595 | $0.92 | $19K |
| 2026-07-09 | 9,702 | $1.26 | $12K |
| 2026-07-02 | 17,762 | $1.07 | $19K |
| 2026-06-04 | 14,982 | $0.97 | $15K |
| 2026-05-04 | 78,382 | $1.22 | $96K |
| 2026-04-24 | 281 | $1.20 | $337 |
| 2026-04-15 | 27,618 | $1.06 | $29K |
| 2026-04-10 | 1,096 | $1.06 | $1K |
| 2026-04-02 | 1,301 | $1.03 | $1K |
| 2026-03-25 | 5,430 | $1.03 | $6K |
| 2026-03-13 | 963 | $1.13 | $1K |
| 2026-02-20 | 7,105 | $1.02 | $7K |
| 2026-02-05 | 14,829 | $0.96 | $14K |
| 2026-01-30 | 540 | $1.04 | $562 |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for TCRX in the last 90 days. The most recent filings are listed below. Latest filing: ZDRAVESKI ZORAN (See Remarks) on 2026-10-01.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | ZDRAVESKI ZORAN | See Remarks | Grant | 300K | $0.00 | $0 | 305K |
| 2026-10-01 | MacBeath Gavin | Chief Executive Officer | Grant | 1.0M | $0.00 | $0 | 1.0M |
| 2025-12-23 | Lynx1 Capital Management LP | 10% owner | Buy | 6K | $0.90 | $6K | 8.0M |
| 2025-12-22 | Lynx1 Capital Management LP | 10% owner | Buy | 76K | $0.90 | $68K | 8.0M |
| 2025-12-19 | Lynx1 Capital Management LP | 10% owner | Buy | 80K | $0.90 | $72K | 7.9M |
| 2025-05-20 | Lynx1 Capital Management LP | TenPercentOwner | Buy | 1.2M | $1.20 | $1.4M | 7.9M |
| 2025-05-19 | Lynx1 Capital Management LP | TenPercentOwner | Buy | 1.4M | $1.20 | $1.7M | 6.7M |
| 2024-12-13 | Nichols Weston | TenPercentOwner | Buy | 100K | $2.90 | $290K | 5.4M |
| 2024-12-12 | Nichols Weston | TenPercentOwner | Buy | 32K | $3.01 | $96K | 5.3M |
| 2024-11-15 | Nichols Weston | TenPercentOwner | Buy | 947 | $4.34 | $4K | 5.2M |
| 2024-09-23 | Klencke Barbara | Director | Buy | 5K | $5.29 | $26K | 45K |
| 2024-08-26 | Klencke Barbara | Director | Buy | 5K | $5.53 | $28K | 40K |
| 2024-08-23 | ZDRAVESKI ZORAN | See Remarks | Exercise or conversion | 55K | $4.85 | $266K | 67K |
| 2024-08-23 | ZDRAVESKI ZORAN | See Remarks | Exercise or conversion | 25K | $3.27 | $82K | 92K |
| 2024-08-23 | ZDRAVESKI ZORAN | See Remarks | Exercise or conversion | 13K | $1.81 | $24K | 105K |
| 2024-08-23 | ZDRAVESKI ZORAN | See Remarks | Exercise or conversion | 64K | $2.49 | $160K | 169K |
| 2024-08-23 | ZDRAVESKI ZORAN | See Remarks | Sell | 165K | $5.78 | $952K | 5K |
| 2024-08-23 | Klencke Barbara | Director | Buy | 5K | $5.69 | $28K | 35K |
| 2023-12-19 | BARBERICH TIMOTHY J | Director | Buy | 317 | $4.97 | $2K | 67K |
| 2023-12-18 | BARBERICH TIMOTHY J | Director | Buy | 29K | $4.89 | $141K | 67K |
| 2023-12-14 | Klencke Barbara | Director | Buy | 5K | $5.08 | $25K | 30K |
| 2023-06-02 | BARBERICH TIMOTHY J | Director | Buy | 38K | $2.63 | $100K | 38K |
| 2023-05-31 | Lynx1 Capital Management LP | TenPercentOwner | Sell | 15K | $2.52 | $38K | 5.2M |
| 2023-05-31 | Lynx1 Capital Management LP | TenPercentOwner | Sell | 10K | $2.51 | $25K | 5.2M |
| 2023-05-31 | Lynx1 Capital Management LP | TenPercentOwner | Sell | 400 | $2.51 | $1K | 5.2M |
| 2022-12-28 | Silver Brian M. | Chief Financial Officer | Buy | 3K | $1.56 | $5K | 33K |
| 2022-12-27 | Silver Brian M. | Chief Financial Officer | Buy | 3K | $1.50 | $4K | 30K |
| 2022-05-18 | SOUTHWELL DAVID P | Chief Executive Officer | Buy | 10K | $3.55 | $36K | 172K |
| 2022-05-18 | SOUTHWELL DAVID P | Chief Executive Officer | Buy | 15K | $3.62 | $54K | 162K |
| 2022-05-11 | 667, L.P. | Director,TenPercentOwner | Buy | 3K | $1.99 | $6K | 256K |
| 2022-05-11 | 667, L.P. | Director,TenPercentOwner | Buy | 23K | $1.99 | $46K | 2.5M |
| 2022-05-10 | 667, L.P. | Director,TenPercentOwner | Buy | 102K | $1.93 | $197K | 1.7M |
| 2022-05-10 | 667, L.P. | Director,TenPercentOwner | Buy | 41K | $1.70 | $69K | 145K |
| 2022-05-10 | 667, L.P. | Director,TenPercentOwner | Buy | 758K | $1.95 | $1.5M | 2.5M |
| 2022-05-10 | 667, L.P. | Director,TenPercentOwner | Buy | 95K | $1.95 | $185K | 253K |
| 2022-05-10 | 667, L.P. | Director,TenPercentOwner | Buy | 13K | $1.93 | $25K | 158K |
| 2022-05-10 | 667, L.P. | Director,TenPercentOwner | Buy | 325K | $1.70 | $553K | 1.6M |
| 2022-03-24 | Silver Brian M. | Chief Financial Officer | Buy | 15K | $3.40 | $51K | 27K |
| 2021-12-23 | SOUTHWELL DAVID P | Chief Executive Officer | Exercise or conversion | 49K | $1.97 | $96K | 147K |
| 2021-09-23 | ZDRAVESKI ZORAN | Chief Legal Officer | Buy | 5K | $7.48 | $35K | 5K |
| 2021-09-21 | MacBeath Gavin | Chief Scientific Officer | Buy | 57 | $6.19 | $353 | 50K |
| 2021-09-21 | Silver Brian M. | Chief Financial Officer | Buy | 5K | $6.32 | $32K | 12K |
| 2021-09-20 | MacBeath Gavin | Chief Scientific Officer | Buy | 5K | $6.22 | $31K | 50K |
| 2021-09-09 | Silver Brian M. | Chief Financial Officer | Buy | 6K | $8.48 | $50K | 7K |
| 2021-09-08 | SOUTHWELL DAVID P | Chief Executive Officer | Buy | 11K | $8.73 | $96K | 98K |
| 2021-08-27 | Desmarais William | Chief Business Officer | Buy | 3K | $9.08 | $23K | 3K |
| 2021-07-20 | Silver Brian M. | Chief Financial Officer | Buy | 1K | $15.00 | $15K | 1K |
| 2021-07-20 | BARBERICH TIMOTHY J | Director | Conversion | 33K | price not stated in the filing | not stated | 33K |
| 2021-07-20 | 667, L.P. | Director | Buy | 1.3M | $15.00 | $19.8M | 1.3M |
| 2021-07-20 | 667, L.P. | Director | Buy | 105K | $15.00 | $1.6M | 105K |
| 2021-07-20 | Westphal Christoph H | TenPercentOwner | Buy | 133K | $15.00 | $2.0M | 1.3M |
| 2021-07-20 | Westphal Christoph H | TenPercentOwner | Conversion | 1.1M | price not stated in the filing | not stated | 1.1M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON11 holders report 5% or more of TCRX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Weston Nichols at 13.1% of the class (20,519,148 shares), filed 2026-08-14 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-09-25 | 13G | Readout Capital, LPinvestment adviser, partnership | 3.5M | 5.4% | 2026-09-21 |
| 2026-09-25 | 13G | Readout Capital GP, LLCparent holding company | 3.5M | 5.4% | 2026-09-21 |
| 2026-09-25 | 13G | Matthew Smithparent holding company, individual | 3.5M | 5.4% | 2026-09-21 |
| 2026-08-14 | 13G/Ano. 4 | LAMPERT MARK Nindividual | 6.4M | 10.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | BVF PARTNERS L P/ILinvestment adviser, partnership | 6.4M | 10.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | BVF INC/ILcorporation | 6.4M | 10.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | BVF GP HOLDINGS LLCother entity | 6.3M | 9.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | BVF I GP LLCother entity | 3.6M | 5.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | BIOTECHNOLOGY VALUE FUND L Ppartnership | 3.6M | 5.7% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | BVF II GP LLCother entity | 2.7M | 4.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | BIOTECHNOLOGY VALUE FUND II LPpartnership | 2.7M | 4.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | BVF Partners OS Ltd.corporation | 83K | 0.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | Biotechnology Value Trading Fund OS LPpartnership | 83K | 0.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Weston Nicholsindividual | 20.5M | 13.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Lynx1 Capital Management LPpartnership | 20.5M | 13.1% | 2026-06-30 |
13F holders
Tracked managers holding TCRX at their latest 13F. JSON5 of the 30 tracked managers held TCRX at their latest 13F, $5.9M in total at quarter-end prices. Two Sigma Investments is the largest at $1.9M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 1.9M | $1.9M | 0.00% | +741K |
| Renaissance Technologies | 2026-06-30 | 1.3M | $1.3M | 0.00% | -38K |
| Millennium Management | 2026-06-30 | 1.2M | $1.1M | 0.00% | -297K |
| Citadel Advisors | 2026-06-30 | 1.0M | $989K | 0.00% | +691K |
| D. E. Shaw & Co. | 2026-06-30 | 548K | $537K | 0.00% | +229K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
TScan Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows TScan Therapeutics (TCRX), SEC CIK 1783328, listed on Nasdaq. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-09-25.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-12.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-01.JSON and CSV
- Company record
- EDGAR filing index for CIK 1783328Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
- SYRESpyre Therapeutics
- SYYSysco
- TAT&T
- TAPMolson Coors
- TCOMTrip.com Group
- TDToronto-Dominion Bank
- TDGTransDigm Group
- TDYTeledyne Technologies
Datasets
Frequently Asked Questions
How much of TCRX is sold short?
What is TCRX's daily short volume?
Does TCRX have fails to deliver?
Are TCRX insiders buying or selling?
Who owns 5% or more of TCRX?
Which tracked 13F managers own TCRX?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.